Tata India Pharma & Healthcare IDCW Payout Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

Tata India Pharma & Healthcare IDCW Payout Direct Plan

NAV
₹36.2744
-0.03%
(20 Aug)
AUM
1,339 Cr
TER
0.61%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+5.6%
-6.5%
-6.5%
-6.5%
-7.0%
3Y
+25.9%
+33.2%
+33.2%
+33.2%
+32.4%
5Y
+20.8%
+30.9%
+30.9%
+30.9%
+29.2%
ALL
+14.3%
+11.9%
+11.9%
+11.9%
+16.5%
VOL
15.6%
20.2%
20.2%
20.2%
20.3%
TER
0.6%
0.8%
0.8%
0.8%
0.9%
AUM
₹1,339 Cr
₹5,278 Cr
₹5,278 Cr
₹5,278 Cr
₹1,391 Cr
INFO
0.91
0.59
0.59
0.59
0.82
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Tata India Pharma & Healthcare IDCW Payout (DP)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Jul
Top holdings
Sun Pharmaceuticals Industries Ltd
10.9%
Cipla Ltd
6.6%
Apollo Hospitals Enterprise Ltd
5.2%
Lupin Ltd
4.8%
A) Repo
4.6%
HealthCare Global Enterprises Ltd
4.4%
Torrent Pharmaceuticals Ltd
4.3%
Aster DM Healthcare Ltd Ordinary Shares
4.3%
Fortis Healthcare Ltd
4.0%
Alkem Laboratories Ltd
4.0%
Top industry exposure
Healthcare
91.7%
Financial Services
1.6%
Basic Materials
0.5%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
34%
Lock-in period
-
Exit load
• 0.25% for redemption within 30 days
Fund objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund manager(s)
Rajat Srivastava

FAQs